185 related articles for article (PubMed ID: 17123261)
1. [Hyperhomocysteinemia in chronic renal failure.].
Satta E; Perna AF; Lombardi C; Acanfora F; Violetti E; Romano MM; Capasso R; Pisano M; Paduano F; De Santo NG
G Ital Nefrol; 2006; 23(5):480-9. PubMed ID: 17123261
[TBL] [Abstract][Full Text] [Related]
2. Metabolic consequences of hyperhomocysteinemia in uremia.
Perna AF; Ingrosso D; Satta E; Romano M; Cimmino A; Galletti P; Zappia V; De Santo NG
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S85-90. PubMed ID: 11576929
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine.
Stam F; van Guldener C; ter Wee PM; Kulik W; Smith DE; Jakobs C; Stehouwer CD; de Meer K
Am J Physiol Renal Physiol; 2004 Aug; 287(2):F215-23. PubMed ID: 15271686
[TBL] [Abstract][Full Text] [Related]
4. Causes of hyperhomocysteinemia in patients with chronic kidney diseases.
Garibotto G; Sofia A; Valli A; Tarroni A; Di Martino M; Cappelli V; Aloisi F; Procopio V
Semin Nephrol; 2006 Jan; 26(1):3-7. PubMed ID: 16412817
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine in uremia.
Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
[TBL] [Abstract][Full Text] [Related]
6. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
Perna AF; Castaldo P; Ingrosso D; De Santo NG
J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
[TBL] [Abstract][Full Text] [Related]
8. Hyperhomocysteinemia and macromolecule modifications in uremic patients.
Perna AF; Capasso R; Lombardi C; Acanfora F; Satta E; Ingrosso D
Clin Chem Lab Med; 2005; 43(10):1032-8. PubMed ID: 16197294
[TBL] [Abstract][Full Text] [Related]
9. Possible mechanisms of homocysteine toxicity.
Perna AF; Ingrosso D; Lombardi C; Acanfora F; Satta E; Cesare CM; Violetti E; Romano MM; De Santo NG
Kidney Int Suppl; 2003 May; (84):S137-40. PubMed ID: 12694330
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action.
Perna AF; Acanfora F; Satta E; Lombardi C; Ingrosso D; De Santo NG
Semin Nephrol; 2004 Sep; 24(5):426-30. PubMed ID: 15490404
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients.
Jungers P; Chauveau P; Bandin O; Chadefaux B; Aupetit J; Labrunie M; Descamps-Latscha B; Kamoun P
Miner Electrolyte Metab; 1997; 23(3-6):170-3. PubMed ID: 9387110
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine metabolism in renal failure.
Perna AF; Ingrosso D; Satta E; Lombardi C; Acanfora F; De Santo NG
Curr Opin Clin Nutr Metab Care; 2004 Jan; 7(1):53-7. PubMed ID: 15090904
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with increased plasma homocysteine in patients using an amino acid peritoneal dialysis fluid.
Yang SY; Huang JW; Shih KY; Hsu SP; Chu PL; Chu TS; Wu KD
Nephrol Dial Transplant; 2005 Jan; 20(1):161-6. PubMed ID: 15572386
[TBL] [Abstract][Full Text] [Related]
14. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation.
van Guldener C; Stam F; Stehouwer CD
Clin Chem Lab Med; 2005; 43(10):1026-31. PubMed ID: 16197293
[TBL] [Abstract][Full Text] [Related]
15. The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art.
Esse R; Barroso M; Tavares de Almeida I; Castro R
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781581
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics in hyperhomocysteinemic states. A special focus on uremia.
Ingrosso D; Perna AF
Biochim Biophys Acta; 2009 Sep; 1790(9):892-9. PubMed ID: 19245874
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine and cardiovascular risk].
Lutteri L; Chapelle JP; Gielen J
Rev Med Liege; 1999 Jun; 54(6):541-7. PubMed ID: 10446525
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine and DNA methylation: a review of animal and human literature.
Mandaviya PR; Stolk L; Heil SG
Mol Genet Metab; 2014 Dec; 113(4):243-52. PubMed ID: 25456744
[TBL] [Abstract][Full Text] [Related]
19. Potential strategies to normalize the levels of homocysteine in chronic renal failure patients.
Massy ZA
Kidney Int Suppl; 2003 May; (84):S134-6. PubMed ID: 12694329
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia.
Perna AF; Ingrosso D; De Santo NG; Galletti P; Zappia V
Kidney Int; 1995 Jan; 47(1):247-53. PubMed ID: 7731153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
